HGH Fragment 176-191, commonly referred to simply as the Fragment, is a synthetic peptide derived from the C-terminal segment of human Growth Hormone (GH). It consists of amino acids 176 through 191 of the full 191-amino-acid GH molecule and was specifically isolated because this region is responsible for GH’s fat-burning (lipolytic) activity, independent of its growth-promoting effects.
HGH Fragment 176-191 (10 vails 2Mg)
Native Growth Hormone exerts multiple systemic effects, including:
- Fat mobilization
- IGF+1 stimulation
- Bone and tissue growth
- Insulin antagonism
Researchers identified that lipolysis is localized primarily in the 176-191 region of GH. By isolating this segment, they created a compound that:
- Preserves fat-burning signaling
- Eliminates IGF-1 stimulation
- Avoids growth-related and diabetogenic effects
Thus, the Fragment was designed as a targeted metabolic peptide, not a growth hormone substitute.
A. Direct Action on Adipose Tissue
HGH Fragment 176-191 binds to receptors on adipocytes (fat cells) and activates intracellular pathways that:
- Stimulate hormone-sensitive lipase
- Increase breakdown of stored triglycerides
- Release free fatty acids for energy use
This action is localized and selective, meaning it targets fat tissue without broadly affecting other organs.
B. Inhibition of Lipogenesis
In addition to promoting fat breakdown, the Fragment:
- Suppresses de novo lipogenesis
- Reduces re-esterification of fatty acids
- Prevents storage of excess calories as fat
This dual mechanism (fT fat release + 4 fat storage) creates a net negative fat balance.
